Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2010 Jun;146(6):682-3.
doi: 10.1001/archdermatol.2010.128.

Persistent prurigo nodularis responsive to initiation of combination therapy with raltegravir

Patrick Unemori, Kieron S Leslie, Toby Maurer
Case Reports

Persistent prurigo nodularis responsive to initiation of combination therapy with raltegravir

Patrick Unemori et al. Arch Dermatol. 2010 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Case 1. Dorsal surface of the left hand prior to commencement of raltegravir therapy.
Figure 2
Figure 2
Case 1. Dorsal surface of the left hand after commencement of raltegravir therapy.
See this image and copyright information in PMC

References

    1. Zancanaro PC, McGirt LY, Mamelak AJ, Nguyen RH, Martins CR. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. J Am Acad Dermatol. 2006;54(4):581–588. - PubMed
    1. Neri S, Ierna D, D’Amico RA, Giarratano G, Leotta C. Helicobacter pylori and prurigo nodularis. Hepatogastroenterology. 1999;46(28):2269–2272. - PubMed
    1. Mattila JO, Vornanen M, Katila ML. Histopathological and bacteriological findings in prurigo nodularis. Acta Derm Venereol. 1997;77(1):49–51. - PubMed
    1. Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol. 2005;46(4):211–220. - PubMed
    1. Markowitz M, Nguyen BY, Gotuzzo E, et al. Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46(2):125–133. - PubMed